MYD88L265P andCXCR4mutations in lymphoplasmacytic lymphoma identify cases with high disease activity

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

(2014) A. Martinez-Trillos et al.   BLOOD

The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

(2014) Y Cao et al.   LEUKEMIA

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia

(2013) G. Yang et al.   BLOOD

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

(2013) M. Varettoni et al.   BLOOD

MYD88 L265P mutation in Waldenstrom macroglobulinemia

(2013) S. Poulain et al.   BLOOD

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms

(2013) M. Varettoni et al.   BLOOD

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

(2013) Z. R. Hunter et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma

(2013) U. Randen et al.   HAEMATOLOGICA

The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-“negative” grade 1/2 follicular lymphomas

(2013) Patrick Adam et al.   HUMAN PATHOLOGY

Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma

(2013) Elisabet E. Manasanch et al.   LEUKEMIA & LYMPHOMA

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

(2012) N Gachard et al.   LEUKEMIA

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Absence of MYD88 gene mutation in acute leukemias and multiple myelomas

(2011) Eun M. Je et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

(2011) Q. Yan et al.   HAEMATOLOGICA

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia

(2008) H. T. Ngo et al.   BLOOD

Targeting NF- B in Waldenstrom macroglobulinemia

(2008) X. Leleu et al.   BLOOD